anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a poultry anticoccidia traditional Chinese medicine oral liquid. The oral liquid is mainly prepared from the following four traditional Chinese medicines: hyperforin perforatum, purslane, sanguisorba officinalis and astragalus membranaceus at a certain weight ratio. Purified water is added to hyperforin perforatum, purslane, sanguisorba officinalis, astragalus membranaceus, a surfactant, an antioxidant and a preservative. Effective extraction of the hyperforin perforatum has obvious anticoccidia activity; the sanguisorba officinalis has hemostatic effects; the purslane is capable of improving the survival rate of chicks, and has the efficacies of detoxifying and clearing heat; and the astragalus membranaceus has the effect of enhancing the immunity of animal organism. The oral liquid is prepared by the following steps: independently extracting the hyperforin perforatum according to the ratio, and filtering; respectively decocting the purslane, the sanguisorba officinalis and the astragalus membranaceus, merging filtrate, concentrating, carrying out ethanol extraction, standing, and filtering to obtain filtrate B; and mixing filtrate A with the filtrate B, applying the surfactant, the antioxidant and the preservative, stirring evenly, filtering, sterilizing to form an oral liquid preparation. The preparation is safe, effective, low in toxic and side effects and free of drug resistance.
The treatment for this study will be the Specific Carbohydrate diet (SCD). Intervention will be based upon standard dietary therapy as well as a nutritional handbook developed in the Gastroenterology division. Patients will receive one-on-one guidance by a Seattle Children's Dietician trained in the SCD during each visit. Prior to each visit patient will fill out a 3 day nutrition log which will be reviewed by the dietician during the clinic visit. Each patient will receive books on the SCD therapy which will include recipes and information about the diet The two books given will include "Breaking the Vicious Cycle" by Elaine Gottschall and "Recipes for the Specific Carbohydrate Diet" by Raman Prasad.
Reductions in absolute forced expiratory volume over 1 second (FEV1) were observed in subjects treated with VELSIPITY as early as 3 months after treatment initiation. In UC-1, the decline in absolute FEV1 from baseline in subjects treated with VELSIPITY compared to placebo was 79 mL (95% CI: -152, -5) at 3 months. In UC-2, reductions in absolute FEV1 were not observed. There is insufficient information to determine the reversibility of the decrease in FEV1 after drug discontinuation. In UC-1 and UC-2, subjects with UC and asthma and/or chronic obstructive pulmonary disease were treated with VELSIPITY; however, interpretation of changes in pulmonary function test measures in this population are limited due to small sample sizes. Spirometric evaluation of respiratory function should be performed during therapy with VELSIPITY if clinically indicated.
OBJECTIVE: This work aimed to construct and validate a model for predicting distant metastasis (DM) in thyroid carcinoma (TC) patients aged≥50.
PATIENTS AND METHODS: The research data were collected from the Surveillance, Epidemiology, and End Results (SEER) program databases via SEER*Stat software (https://seer.cancer.gov/). Logistics regression was used to screen the independent risk factors for TC patients. The nomogram was constructed and validated based on the logistics regression results for predicting DM occurrence in TC patients. Moreover, the characteristic curves (ROC) were used to assess the predictive performance. The decision analysis curve (DCA) and the calibration curve were used to test this nomogram's accuracy and discrimination. Additionally, we analyzed survival and risk scores in TC patients with metastasis using the Kaplan-Meier (KM) method.
RESULTS: A total of 11,166 TC patients were divided into a training set and a validation set. The results showed that topography (T), lymph node metastasis (N), and (grade) G were crucial risk factors for predicting DM. ROC analysis showed that the model had a good discriminative ability both in the training and validation set. The DCA curve showed greater net benefits across a range of DM risks for the nomogram in the training and validation set. Survival analyses showed that the metastasis cases with low-risk scores have shown a poorer prognosis in this study, both in the training and validation set.
CONCLUSIONS: The nomogram model had excellent predictive performance and net benefit for predicting DM of TC patients aged ≥50. The model can help doctors develop treatment plans for their patients.
To reduce the development of drug-resistant bacteria and maintain the effectiveness of levofloxacin tablets and other antibacterial drugs, levofloxacin tablets should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.   
Culture and susceptibility testing   
Appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing the infection and to determine their susceptibility to levofloxacin [see Microbiology (12.4)] .Therapy with levofloxacin tablets may be initiated before results of these tests are known; once results become available, appropriate therapy should be selected.   
As with other drugs in this class, some isolates of Pseudomonas aeruginosa may develop resistance fairly rapidly during treatment with levofloxacin tablets. Culture and susceptibility testing performed periodically during therapy will provide information about the continued susceptibility of the pathogens to the antimicrobial agent and also the possible emergence of bacterial resistance.
The study design used was a randomized controlled trial (RCT) with double blinds. Double blind because neither the patient, the lead investigator, nor the investigator on record knew the drug or placebo that was administered. Research subjects were selected consecutively in patients who will undergo lower extremity surgery at the Cipto Mangunkusumo National Central General Hospital. Forty-eight research subjects will be divided into two groups, namely the group given Intravenous Magnesium Sulfate 30 mg/kgBW and the group given a placebo. Research subjects were randomized by type of surgery using randomization software by research assistants. The results of randomization were not known to the patient, the principal investigator, or the researcher taking notes.

This study aims to determine the effect of adding 30 mg/kg body weight of intravenous MgSO4 to 30 mg of ketorolac on the degree of pain and the need for opioids after lower extremity surgery.
512,196. Toxins and the like. LEDERLE LABORATORIES, Inc. Aug. 12, 1938, No. 23806. Convention date, Aug. 19, 1937. [Class 81 (i)] Pertussis (Whooping cough) toxin or Toxoid is prepared by growing cultures of pertussis bacilli in a medium of soluble-starch broth, vegetable extract broth or semi-solid agar, separating the bacilli from the culture medium by filtration and preserving the filtrate for use as a toxin or detoxifying it to form a toxoid. The bacilli are cultivated for about 48 hours at a temperature of 37‹C. under an atmosphere of about 1 part of carbon dioxide and 4 parts of oxygen by volume. The detoxification is effected when desired bv the addition of a small amount of formalin to the filtered solution, about 0.3 per cent. of 40 per cent. strength, and keeping the mixture at about 40‹C. for two to three weeks.
The Severe Acute Respiratory Syndrome-Corona Virus-2 (SARS-CoV-2) viral composition is determined by Next Generation sequencing (different protocols for enrichment are available, and are currently being tested to successfully analyse the virus from different isolates). It is known that SARS-CoV-2 sequence is changing at least one position every second passing from person to person. Numerous variants have been described deriving from 3 different ancestral viruses (named A, B, and C) reflecting different distributions in East Asia, Europeans and Americans. At it is anticipated that other (super)infections may add to the severity of the infection and disease course, the entire metagenome of the throat is being sequenced and analyzed as well.
Discuss the availability of naloxone for the emergency treatment of opioid overdose with the patient and caregiver. Because patients being treated for opioid use disorder have the potential for relapse, putting them at risk for opioid overdose, strongly consider prescribing naloxone for the emergency treatment of opioid overdose, both when initiating and renewing treatment with Buprenorphine and Naloxone Sublingual Tablets. Also consider prescribing naloxone if the patient has household members (including children) or other close contacts at risk for accidental ingestion or opioid overdose [see Warnings and Precautions (5.2)].

Advise patients and caregivers that naloxone may also be administered for a known or suspected overdose with Buprenorphine and Naloxone Sublingual Tablets itself. Higher than normal doses and repeated administration of naloxone may be necessary due to the long duration of action of Buprenorphine and Naloxone Sublingual Tablets and its affinity for the mu opioid receptor [see Overdosage (10)].

Inform patients and caregivers of their options for obtaining naloxone as permitted by individual state naloxone dispensing and prescribing requirements or guidelines (e.g., by prescription, directly from a pharmacist, or as part of a community-based program) [see Patient Counseling Information (17)].
Participants in Panel A and B will self-administer intranasal placebo on Days 1 and 4 during the double-blind phase. Depending on response on Day 8, participants will receive intranasal placebo on Days 8 and 11 or be re-randomized to receive intranasal placebo or esketamine at a dose of 28 mg, 56 mg, or 84 mg (Panel A) or 14 mg or 56 mg (Panel B) on Day 8 and Day 11.
It is common knowledge that women with pelvic floor dysfunction will develop, initiate and adopt behaviors which mitigate their symptoms or impairment. For some women, this involves wearing a pad and for others, knowledge of restroom locations. Little is known about the role of such behaviors in helping women adapt to urinary incontinence (UI), pelvic organ prolapse (POP), or fecal incontinence (FI). Additionally, there are no studies that address the persistence of these behaviors following treatment as measured by traditional outcomes. Results of a pilot study that assessed quality of life (QOL) in women with pelvic floor disorders (PFD) indicated that women relied heavily on behavioral adaptation in order to cope with PFD symptoms. Subsequently, a draft Adaptation Index was developed with input from investigators of the Pelvic Floor Disorders Network (PFDN). This measure was further refined by focus groups as part of the 1J06 protocol. The 1J06 study is investigating the properties of this tool in subjects with UI and POP. This study focuses on the validation of this instrument as a measurement of adaptive behaviors used to reduce symptoms of FI and to describe the use of adaptive behaviors among women with FI.
Each subject will receive a SILK lenticule removal procedure on one eye and a commercially available laser vision correction procedure on their fellow eye (Feasibility Phase). Subjects will receive a lenticule removal procedure on both eyes to reduce or eliminate myopic refractive errors (Pivotal Phase). The second eye treatment will be considered only after the first eye 1-week follow up visit has been completed and safety criteria are met.
Subjects will take 1 day of metoprolol followed by a 7 day wash out period, then 2 days of pyronaridine-artesunate followed by 1 day of pyronaridine-artesunate + metoprolol, followed by a 87 day follow-up period. Subjects will then receive pyronaridine-artesunate once daily for 3 days followed by a 40 day follow-up period.
Method of increasing the biological availability of interally administered medicaments which are degradable (esp. reducible) by the contents of the stomach or intestines, comprises administering the medicaments together with additives which undergo degradation (esp. redn.) in preference to the medicaments. Relevant medicaments include chloramphenicol, aureomycin, tetracycline antibiotics, digoxin, barbiturates, stilbenes, vitamins, nitrofurantoin, 1,4-benzodiazepines, nitroglycerin and nitrate and nitrite esters. Suitable additives include cystine, dehydroascorbic acid, riboflavine and pyridoxal.
Participants will first receive a message enjoining them to consider 2 peers who would want them to vaccinate. Then they will be asked to do those peers a favor by getting a vaccine at their next opportunity. They will receive a reminder 3 days later.
<P>PROBLEM TO BE SOLVED: To provide an elucidation of a target gene of a PGI2-PPARδ transmission system and a new inflammatory disease-treating agent by taking the PGI2-PPARδ transmission system as the target.  <P>SOLUTION: This target of the PG (prostaglandin) I2-PPAR (peroxisome proliferator-activated receptor) δ transmission system is found to be an IL (interleukin)-13 gene by a microarray analysis. The association of a PGI2-PPARδ-IL-13 pathway with cellular adhesion is examined, and a fact that the production of the IL-13 mediated by the PPARδ inhibits the adhesion of monocytes with endothelium cells markedly is elucidated. The association between the PGI2-PPARδ-IL-13 pathway and COX (cyclooxygenase)-2 is examined, and it is found that the IL-13 production mediated by PGI2/PPARδ inhibits the expression of the COX-2. It is known that the monocyte-endothelium cell adhesion and COX-2 are related to the inflammation. Therefore, it is possible to use a cell adhesion inhibitor or COX-2 inhibitor by taking the PGI2-PPARδ-IL-13 pathway as the target can be utilized as an anti-inflammatory agent.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Pregnant women with fasting glucose \< 5.1 mmol/L (92 mg/dL), 1 h glucose \< 10.0 mmol/L (180 mg/dL) and 2 h glucose \< 8.5 mmol/L (153 mg/dL) were considered as healthy controls. Controls were randomly selected and individually matched to cases by age (± 2 years), gestational age (± 2 weeks) and parity.
A system and method for optimizing trial design for clinical trials. The system includes a computer system and a processor communicably coupled to a memory. The processor processes and structures raw trial data to a format suitable for input to train a machine learning model. The processor further identifies plurality of independent features of the raw trial data and screens actionable features. Further, the processor computes cut off range values for each of the actionable features and form a plurality of sub-groups of patients. The processor simulates patient response of each of the plurality of sub-groups of patients and identifies a sub-group of patients based upon population percentage and delta response that shows optimal clinical trial results in the simulated patient response.
PURPOSE:To obtain the temp. sensitive liposome which can release included materials at a specific temp. and is applicable in medical and pharmaceutical fields, such as drug carriers in drug delivery systems. CONSTITUTION:A high-polymer compd. having clouding points is deposited on or in the conventional lipid liposome to obtain the temp. sensitive liposome. The high-polymer compd. deposited on or in the liposome is hydrophobed at the temp. near the clouding point of such liposome and, therefore, disturbance is generated in the structure of the liposome film and the release of the included materials arises. The high-polymer compd. having the clouding points is adequately polyacrylic acid polymers, such as poly-N-isopropyl acrylamide. The high- polymer compd. is stably deposited on the liposome surface if a hydrophobic group, such as alkyl group or cholesterol, is introduced therein.
Patients receive obinutuzumab IV over 30 minutes on days 1, 8, and 15 of cycle 1, and day 1 of cycles 2-6. Patients also receive ibrutinib PO QD on days 1-28. Treatment repeats every 28 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients who have PR continue to receive obinutuzumab IV every 2 months and ibrutinib PO QD for 2 years in the absence of disease progression or unacceptable toxicity.
In this low-moderate resistance training group, participants will perform warm-up activity for 15 minutes then low-moderate intensity resistance exercises with 120 seconds of rest interval between each set of exercise and between exercises respectively. After that, generalized stretching exercises as a cool down activity will be performed by the participants. Participants will perform exercises twice weekly, 40-50 minutes/session for 12 weeks under supervision.
Objectives. Musculoskeletal (MSK) complaints are prevalent in law enforcement officers (LEOs), but research that examines their risk factors is limited. This study aimed to identify the self-reported MSK complaint prevalence and perceived causes in LEOs. Methods. The Nordic musculoskeletal questionnaire was used to identify the 12-month and 7-day prevalence of MSK 'trouble' (ache, pain, discomfort) for nine body sites. The perceived cause, participant characteristics and occupational role were reported. Body fat percentage was measured using bioelectrical impedance. Results. Complete submissions of 186 questionnaires were received (80% male, median age 40.6 years, interquartile range 10.1). Eighty-six per cent of officers reported having an MSK complaint in the last 12 months, where lower back, shoulder and neck complaint prevalence was 59.1, 48.4 and 42.5%, respectively. The occupational role was associated with the site and presence of complaints (p < 0.05), where armed officers presented with more shoulder, lower back and hip/thigh complaints. Age, sex and body fat did not impact complaint prevalence. Participants mainly attributed their complaints to occupation equipment or to sport and exercise. Conclusion. MSK complaints were highly prevalent in this cohort, particularly armed officers. Further research is required to establish the impact of these complaints and how they can be mitigated.
Patients receive ipatasertib PO QD on days 1-21, capecitabine PO BID on days 1-7 and 15-21, and atezolizumab IV over 30-60 minutes on days 1 and 15. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity.
FIELD: medicine, therapy, homeopathy. SUBSTANCE: invention relates to cough treatment. Method involves administration in body the activated form of antibodies raised to morphine taken in small or supersmall doses prepared by multiple successive dilution and external effect by homeopathic technology. Method allows to eliminate cough rapidly due to effect on central links of cough reflex being without adverse effects. EFFECT: enhanced effectiveness of method. 2 cl, 3 ex
Vaginal delivery of low-risk pregnancies is best provided and guided by a midwife. It is seen that receiving support from a midwife in the birth of low-risk pregnancies does not increase the risks for the mother or newborn and has many economic and emotional advantages. The World Health Organisation recommends respectful care based on woman-centred care in the intapartum period for a positive birth experience. Respectful Maternity Care has been recognised as a key strategy to improve the quality of maternity care. Although there is no clear consensus on the definition of respectful maternity care, it is generally considered synonymous with intimate and woman-centred care. It is a care approach that emphasises the fundamental rights of women, newborns and families and increases adequate access to evidence-based care while recognising their needs and preferences. In this direction, midwives are expected to add respectful maternity care to their clinical skills in the management of the birth process. In the literature, it is seen that respectful and helpful interaction between women and health professionals during labour creates positive perceptions in women. In the study of Liu et al. (2021), it is stated that midwife-led management of labour leads to the formation of positive perceptions in women. Fear of labour, labour pain and duration of labour in midwife-led care on the behaviour of the students in the study.
JESDUVROQ increases the risk of arterial and venous thrombotic events, that may be fatal, including myocardial infarction, stroke, venous thromboembolism and vascular access thrombosis [see Boxed Warning, Adverse Reactions (6.1)]. Patients with cardiovascular or cerebrovascular disease are at increased risk of these events. Avoid use in patients with a history of myocardial infarction, cerebrovascular event, or acute coronary syndrome within the 3 months prior to starting JESDUVROQ.

A rate of hemoglobin rise of greater than 1 g/dL over 2 weeks may contribute to these risks. Targeting a hemoglobin level of greater than 11 g/dL is expected to further increase the risk of death and arterial and venous thrombotic events, as occurs with ESAs, which also increase erythropoietin levels.

No trial has identified a hemoglobin target level, dose of JESDUVROQ, or dosing strategy that does not increase these risks. Use the lowest dose of JESDUVROQ sufficient to reduce the need for red blood transfusions. Adherence to dosing and hemoglobin monitoring recommendations is important to avoid excessive erythropoiesis [see Dosage and Administration (2.4)].

Advise patients to seek immediate medical attention if they develop signs or symptoms of myocardial infarction, stroke, venous thromboembolism, or thrombosis of vascular access. Evaluate and manage promptly if these occur.
Products for oxidatively changing the color of keratinic fibers include at least two preparations (A) and (B), which are produced separately from one another. The first preparation (A) includes, in a cosmetic carrier, (A1) hydrogen peroxide and (A2) at least one chelating agent chosen from a group of specific chelating agents. The second preparation (B) includes, in a cosmetic carrier, (B1) at least one alkalizing agent. The preparation (A) is produced in a first container (container A). The first container includes at least two layers: an inner layer that includes a layer of a synthetic polymer (I) and an outer layer that includes a metal layer. Preparation (B) is produced in a second container (container B), which includes at least two layers: an inner layer that includes a layer of a synthetic polymer (I) and an outer layer that includes a metal layer.
Gingko biloba is a complementary or alternative medication used for purported cognitive enhancing effects. Despite its widespread use there is limited data regarding potential for drug interactions. The purpose of this study is to determine the effect of administration of ginkgo for 4 weeks on single dose phenytoin pharmacokinetics. Eight healthy volunteers will take a single 500mg dose of phenytoin capsules orally with serial blood samples collected over 96 hours for determination of phenytoin pharmacokinetics. Following the pharmacokinetic study subjects will begin taking 2, 60mg capsules (120mg total) of ginkgo twice daily for 28 days. Following 28 days of ginkgo subjects will then again undergo phenytoin pharmacokinetic evaluations with blood samples obtained over 96 hours for determination of phenytoin pharmacokinetics. The ratio of geometric means for phenytoin pharmacokinetic parameter values and 90% confidence intervals about the ratio of log transformed parameter values will be calculated. Confidence intervals falling within the 80-125% range will characterize the pharmacokinetic parameter values before and after ginkgo to be equivalent.